Little patients, losing patience: pediatric cancer drug development

被引：36
作者：
Boklan, Jessica [1 ]
机构：
[1] Phoenix Childrens Hosp, Ctr Canc & Blood Disorders, Phoenix, AZ 85016 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2006年 / 5卷 / 08期
关键词：
D O I：
10.1158/1535-7163.MCT-06-0179
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1905 / 1908
页数：4
相关论文
共 18 条
  • [1] *ASS TASK FORC CHI, DEC MAK RES PART
  • [2] *BIOT IND ORG, HIST PED STUD RUL LE
  • [3] The price of innovation: new estimates of drug development costs
    DiMasi, JA
    Hansen, RW
    Grabowski, HG
    [J]. JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) : 151 - 185
  • [4] *FDA, 2006, PED EXCL STAT FEB 28
  • [5] Regulatory approvals of pediatric oncology drugs: Previous experience and new initiatives
    Hirschfeld, S
    Ho, PTC
    Smith, M
    Pazdur, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 1066 - 1073
  • [6] ISSA JP, 2005, 47 AM SOC HERM ANN M
  • [7] Cancer statistics, 2004
    Jemal, A
    Tiwari, RC
    Murray, T
    Ghafoor, A
    Samuels, A
    Ward, E
    Feuer, EJ
    Thun, MJ
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (01) : 8 - 29
  • [8] MEADOWS M, 2003, DRUG RES CHILDREN
  • [9] MILLER RW, 1995, CANCER, V75, P395, DOI 10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO
  • [10] 2-W
12